Replies to post #71482 on NanoViricides Inc. (NNVC)

[drkazmd65]

Cool,... one step at a time,... that's how we'll get there.

:D

Have a great morning all.

[changes_iv]

Nanoviricides, Inc. does not employ tiny hands or nano-hands/fingers to plug-in several ligands at a single point on the nanomicelle small surface.

“We have clearly demonstrated that the design platform technology for nanoviricides allows development of powerful broad-spectrum antiviral drugs,” said Anil R. Diwan, PhD, President and Chairman of the Company,

“We have developed a small chemical ligand that mimics both the mammalian (or a-2,6-) and avian (or a-2,3) forms of the native sialic acid receptor of influenza viruses. We can design a nanoviricide to exhibit several ligands at a single point, and each nanomicelle may exhibit several hundred ligands on its small surface. The ligands are designed to look very much like (mimic) the sialic acid to the influenza viruses, and the high density of the ligands would force the virus to land onto the nanoviricide and get destroyed by the hidden ‘tails’ of the nanomicelle that snap out and merge into the viral surface lipid coat.”

In the development of their breakthrough nanotechnology Nanoviricides, Inc. may be employing something like this...

Dengue virus research (DengueCide)

In 2010, Harris entered into a research agreement with NanoViricides, Inc. (NNVC).[4] Under this agreement, Harris and coworkers will evaluate the effectiveness of NanoViricides' drug candidates against various dengue viruses. Cell culture models, as well as in vivo animal studies will be employed for testing the drug candidates. The company believes that a viricidal nanoparticle under development can be expected to lead to a broad-spectrum, anti-dengue antiviral treatment, capable of attacking all four dengue virus serotypes and their variant strains. Currently, there are no approved vaccines for the prevention of dengue, nor are there drugs for treatment of dengue virus infection. The worldwide market size for an effective anti-dengue treatment may be as large as that for Hepatitis C virus treatment, or in the billions of dollars, based on current population exposure data.

Using computer modeling, the company noted that it had developed a library of small chemical ligands that bind to dengue virus envelope proteins. Using these ligands, a number of candidate viricidal nanoparticles that are capable of attacking the dengue virus have been developed. The company believes that these viricidal drug candidates mimic the natural, common attachment function by which the four different dengue virus serotypes bind to the body's host cells. http://en.wikipedia.org/wiki/Eva_Harris

“We are very excited about this association with the Harris Lab [...] We will now be able to rapidly advance our anti-dengue therapeutics program.” —Eugene Seymour, CEO of NanoViricides

The highly advanced computer modeling/software employed by Nanoviricides Inc. required training/time to learn. Now, Nanoviricides, Inc. team is ready to move to market. The computer modeling system must be highly developed to interface with highly advanced instruments/equipment that will be able to produce identical batches of an optimized Nanoviricide in the soon to be completed and new Shelton, CT cGMP Pilot Plant.

FluCide

The Company has previously reported that its anti-influenza drug candidates have reduced viral loads from tens to hundreds of times lower levels than oseltamivir (Tamiflu®), depending upon the particulars of the experiment. The FluCide™ oral and injectable drug candidates also protected the lungs of the animals much better than did oseltamivir, indicating a clear benefit. The protection from influenza virus was clearly reflected in the strong increase in survival time in the FluCide-treated animals as compared to oseltamivir. Mice serve only as a “test tube” in these studies, since our drugs are designed to attack the virus particles directly. Thus these positive results in animal studies are expected to correlate well with the human clinical trials.

“We are rapidly advancing towards our goal of filing an IND with the FDA for Influenza based on the guidance we received in our previous pre-IND meeting with the FDA,” said Anil R. Diwan, President of the Company.